Completed PHASE1 INTERVENTIONAL 1-arm NCT03029338

CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell Lymphoma

Sponsor: Institute of Hematology & Blood Diseases Hospital, China

Conditions Lymphomas Non-Hodgkin's B-Cell Relapse

Updated 10 times since 2017 Last updated: Feb 9, 2026 Started: Jun 8, 2017 Primary completion: May 22, 2019 Completion: Jun 22, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Lymphomas Non-Hodgkin's B-Cell and Relapse, this trial is completed. The trial is conducted by Institute of Hematology & Blood Diseases Hospital, China and has accumulated 10 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1
Sep 2024 — Feb 2026 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1
Feb 2022 — Oct 2023 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed

▶ Show 5 earlier versions

Jan 2021 — Feb 2022 [monthly]

Active Not Recruiting PHASE1
Jul 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1
Apr 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE1
Sep 2019 — Apr 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Feb 2017 — Sep 2019 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Institute of Hematology & Blood Diseases Hospital, China
Juventas Cell Therapy Ltd.

Data source: Institute of Hematology & Blood Diseases Hospital, China

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tianjin, China